Who owns BioCryst Pharmaceuticals?

Key details on BioCryst Pharmaceuticals (Ticker: BCRX)

Who owns BioCryst Pharmaceuticals?

Is BCRX a good stock to own? Find out who bought BioCryst Pharmaceuticals, who sold BioCryst Pharmaceuticals (BCRX) stock, and who holds a large position in BioCryst Pharmaceuticals.

Fund Name Number of Shares Share Valuation As Of
Baker Bros. Advisors 6.70M $50.92M Dec. 31, 2013
RA Capital Management 4.35M $33.04M Dec. 31, 2013
Wellington Management Company 2.63M $19.16M Sept. 30, 2013
FMR 2.60M $19.79M Dec. 31, 2013
D. E. Shaw & Co 2.44M $18.55M Dec. 31, 2013
VHCP Management 1.75M $13.33M Dec. 31, 2013
Vanguard 1.74M $13.28M Dec. 31, 2013
TPG Group Holdings 1.16M $8.46M Sept. 30, 2013
TPG Capital 1.16M $3.21M Sept. 30, 2011
BlackRock Institutional Trust Company, N.A. 1.13M $8.60M Dec. 31, 2013
SUSQUEHANNA INTERNATIONAL 1.01M $7.66M Dec. 31, 2013
Deerfield Management Company 868570 $6.60M Dec. 31, 2013
BlackRock Fund Advisors 834789 $6.34M Dec. 31, 2013
Driehaus Capital Management 702175 $2.98M Sept. 30, 2012
STATE STREET CORPORATION 682003 $968444 Dec. 31, 2013
Millennium Management 643755 $4.89M Dec. 31, 2013
T. Rowe Price Associates 615000 $873300 Dec. 31, 2012
MORGAN STANLEY 533012 $4.05M Dec. 31, 2013
QVT Financial 525734 $4.00M Dec. 31, 2013
Technical Financial Services 499516 $3.80M Dec. 31, 2013
NORTHERN TRUST 495047 $762372 June 30, 2013
BOGLE INVESTMENT MANAGEMENT L P /DE/ 386089 $2.81M Sept. 30, 2013
Jennison Associates 357352 $2.72M Dec. 31, 2013
Connor, Clark & Lunn Investment Management 316878 $2.56M Dec. 31, 2013
SMITH ASSET MANAGEMENT 291983 $2.22M Dec. 31, 2013
FRANKLIN STREET ADVISORS INC /NC 289550 $1.23M Sept. 30, 2012
Cormorant Asset Management 268000 $2.04M Dec. 31, 2013
TIAA-CREF Investment Management 235008 $279659 March 31, 2013
Visium Asset Management 234900 $1.79M Dec. 31, 2013
Jacobs Levy Equity Management 233447 $989815 Sept. 30, 2012
Sunrise Partners Limited Partnership 229064 $355049 June 30, 2013
UBS AG 228557 $354263 June 30, 2013
Geode Capital Management 205526 $1.50M Sept. 30, 2013
Perceptive Advisors 197500 $1.50M Dec. 31, 2013
JPMORGAN CHASE & CO 191350 $759659 June 30, 2012
GOLDMAN SACHS 184941 $1.35M Sept. 30, 2013
Jane Street Holding 181665 $1.32M Sept. 30, 2013
Bridgeway Capital Management 160000 $227200 Dec. 31, 2012
Barclays 159290 $1.12M Sept. 30, 2013
Bank of America Corporation 153009 $306018 Dec. 31, 2011
CalPERS 150100 $636424 Sept. 30, 2012
Hutchin Hill Capital 150000 $726000 March 31, 2012
Renaissance Technologies 149003 $591541 June 30, 2012
Eudaimonia Asset Management 148081 $1.08M Sept. 30, 2013

Who sold BioCryst Pharmaceuticals?

Fund Name Date Sold Number of Shares Sold Share Valuation
BAM Capital Dec. 31, 2010 861485 $4.45M
Tradeworx Dec. 31, 2009 163486 $1.06M